Consistently, RA-specific clinical indicators, including RF, CCP, ESR, and CRP were significantly reduced after treatment only in the response group, as compared to the values before the treatment (P < 0.05) or to those in the non-response group after the treatment (P < 0.05). This evidence concerns the gene ESR1 and rheumatoid arthritis.